Swiss pharmaceutical company Roche Group has suspended a late-stage trial for a new rheumatoid arthritis and lupus drug after several patients died from infections. According to Roche, the drug, ocrelizumab, was developed together with Biogen Idec with headquarters in Cambridge, Mass. A review found “the safety risk outweighs the benefits observed in these specific patient populations at this time” after detecting “serious and opportunistic infections, some of which were fatal,” Basel-based Roche said. It declined to say how many patients died, where and when. The company said it was still testing ocrelizumab for patients with relapsing remitting multiple sclerosis.
Source: Associated Press
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.